| Product Unit Size | Cost | Quantity | Stock |
|---|
Luteinizing hormone-releasing hormone (LHRH or Gonadotropin-releasing hormone [GnRH]) is an endogenous peptide hormone that binds the GnRH receptor, stimulating secretion of reproductive hormones (such as luteinizing hormone [LH ] and follicle-stimulating hormone [FSH]) from the pituitary gland. Analogs of GnRH are clinically used to treat hormone-dependent diseases such as prostate and breast cancer, hyperplasia, and endometriosis.
| Cas No. | 86073-88-3 |
|---|---|
| Purity | ≥95% |
| Formula | C60H73N15O13 |
| Formula Wt. | 1212.36 |
| IUPAC Name | 5-Oxo-L-prolyl-L-histidyl-L-tryptophyl-L-seryl-L-tyrosylglycyl-L-tryptophyl-L-leucyl-L-prolylglycinamide |
| Synonym | Gonadotropin-releasing hormone (salmon), LHRH, GnRH |
| Solubility | Soluble in DMSO. |
| Store Temp | -20°C |
|---|---|
| Ship Temp | Ambient |
| MSDS | |
|---|---|
| Info Sheet |
Limonta P, Manea M. Gonadotropin-releasing hormone receptors as molecular therapeutic targets in prostate cancer: Current options and emerging strategies. Cancer Treat Rev. 2013 Oct;39(6):647-63. PMID: 23290320.
Millar RP, Newton CL. Current and future applications of GnRH, kisspeptin and neurokinin B analogues. Nat Rev Endocrinol. 2013 Aug;9(8):451-66. PMID: 23817290.
Wu HM, Wang HS, Huang HY, et al. Gonadotropin-releasing hormone type II (GnRH-II) agonist regulates the invasiveness of endometrial cancer cells through the GnRH-I receptor and mitogen-activated protein kinase (MAPK)-dependent activation of matrix metalloproteinase (MMP)-2. BMC Cancer. 2013 Jun 20;13:300. PMID: 23786715.
Burel D, Li JH, Do-Rego JL, et al. Gonadotropin-releasing hormone stimulates the biosynthesis of pregnenolone sulfate and dehydroepiandrosterone sulfate in the hypothalamus. Endocrinology. 2013 Jun;154(6):2114-28. PMID: 23554453.